CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026
In a major biopharmaceutical industry consolidation, Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, significantly strengthening its position in immunology, rare diseases, and nephrology markets. The acquisition brings together two companies with strong expertise in complement biology and innovative therapeutics, marking a critical step in Biogen’s long-term growth strategy.
Strategic Expansion into Immunology and Rare Diseases
The acquisition will immediately enhance Biogen’s portfolio by adding two FDA-approved therapies — EMPAVELI® and SYFOVRE®, both of which target the complement pathway, a key component of the immune system linked to multiple serious diseases. These therapies have already demonstrated strong commercial traction, generating $689 million in combined revenue in 2025, with projections indicating mid-to-high teen growth rates through 2028.
EMPAVELI® is approved for rare kidney diseases such as C3 glomerulopathy (C3G) and IC-MPGN, as well as paroxysmal nocturnal hemoglobinuria (PNH), while SYFOVRE® is the first approved treatment for geographic atrophy, a leading cause of blindness. The addition of these therapies positions Biogen to expand its footprint in both nephrology and ophthalmology, two high-growth therapeutic areas with significant unmet medical needs.
Commercial and Pipeline Synergies Driving Growth
Advertisement
A key highlight of the deal is the combination of Biogen’s global commercialization capabilities with Apellis’ specialized expertise in complement science. This synergy is expected to maximize the commercial potential of both approved drugs while accelerating development of pipeline assets such as felzartamab, currently in Phase 3 trials for kidney diseases.
Biogen anticipates that the transaction will be accretive to earnings per share (EPS) starting in 2027, with a significant boost to its long-term revenue growth trajectory. The acquisition also provides access to Apellis’ established U.S. sales infrastructure and nephrology capabilities, which are expected to enhance Biogen’s readiness for future product launches and expand its global market reach.
Financial Structure and Regulatory Considerations
Under the terms of the agreement, Biogen will acquire Apellis shares at $41 per share in cash, along with a contingent value right (CVR) tied to future sales milestones of SYFOVRE®. The deal represents a significant premium to Apellis’ recent trading prices and reflects strong confidence in the commercial and clinical potential of its portfolio.
The transaction has been approved by the boards of both companies and is expected to close in the second quarter of 2026, subject to customary regulatory approvals and closing conditions. From a cGxP perspective, the acquisition will require careful integration of quality systems, regulatory compliance frameworks, and manufacturing operations, ensuring continuity of supply and adherence to global GMP and regulatory standards.
Industry Impact and Future Outlook
This acquisition underscores a broader industry trend toward strategic consolidation in the biopharma sector, particularly in areas with high unmet need such as rare diseases and immune-mediated conditions. By combining innovative science, commercial assets, and pipeline strength, Biogen is positioning itself as a leader in next-generation immunology therapies.
The deal is expected to not only enhance shareholder value but also accelerate the delivery of life-changing treatments to patients worldwide, reinforcing the importance of innovation, regulatory excellence, and commercialization efficiency in the evolving pharmaceutical landscape.
Source: Biogen Apellis press release
